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Summary
Immunological memory provides rapid protection to pathogens previously
encountered through infection or vaccination. CD4 T-cells play a central
role in all adaptive immune responses. Vaccines must, therefore, activate
CD4 T-cells if they are to generate protective immunity. For many dis-
eases, we do not have effective vaccines. These include human immunode-
ficiency virus (HIV), tuberculosis and malaria, which are responsible for
many millions of deaths each year across the globe. CD4 T-cells play
many different roles during the immune response coordinating the
actions of many other cells. In order to harness the diverse protective
effects of memory CD4 T-cells, we need to understand how memory CD4
T-cells are generated and how they protect the host. Here we review
recent findings on the location of different subsets of memory CD4
T-cells that are found in peripheral tissues (tissue resident memory T-
cells) and in the circulation (central and effector memory T-cells). We dis-
cuss the generation of these cells, and the evidence that demonstrates how
they provide immune protection in animal and human challenge models.
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Introduction
Vaccines are the most cost-effective form of healthcare
worldwide. Most current vaccines act by generating pro-
tective antibodies that inactivate the pathogen or its tox-
ins.1 We do not, however, have effective vaccines against
pathogens responsible for many millions of deaths each
year, such as human immunodeficiency virus (HIV),
malaria and tuberculosis. These pathogens present diffi-
cult challenges to the immune system either through their
complex life cycles and/or via their ability to impair or
subvert the host’s immune response. Protective immunity
to these infections requires a more diverse immune
response than antibodies alone. CD4 T-cells are central to
all adaptive immune responses, coordinating pathogen
control and clearance by both immune and local stromal
cells. Harnessing their diverse functions has the potential
to provide novel vaccine strategies that generate effective
immunity against even complex infections.
CD4 T-cells act in concert with innate and other adaptive
immune cells to protect the host from pathogens. During
primary immune responses, CD4 T-cells are activated in
secondary lymphoid organs where they amplify the anti-
pathogen response by driving B-cell germinal responses
and supporting CD8 T-cell activation. Activated CD4 T-
cells also migrate from secondary lymphoid organs to
inflamed sites where they participate in controlling and/or
clearing the pathogen. Following pathogen control or clear-
ance, the vast majority of activated CD4 T-cells undergo
apoptosis with the remainder, usually around 10%, form-
ing a population of long-lived memory cells. These memory
cells retain knowledge about the initial immune response,
enabling them to respond more effectively following a sec-
ondary infection. This enhanced response forms the basis
for the success of vaccines. Understanding the signals that
drive the generation of protective memory CD4 T-cells and
the mechanisms by which they act will facilitate the design
and development of improved vaccines.
Cytokine production is key to CD4 T-cell
protective immunity
Na€ıve CD4 T-cells can differentiate into a number of dis-
tinct functional subsets.2,3 This enables them to tailor the
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immune response depending on the type of pathogen, and
to perform multiple functions at different sites during a
single infection. Memory CD4 T-cells retain characteristics
of the activated CD4 T-cells from which they are derived
and can, therefore, also be divided based on their func-
tional responses.4,5 This cellular memory is thought to be
retained by epigenetic changes to the cell’s DNA or associ-
ated histone proteins that keep genes in an open or closed
state depending on their expression during the primary
immune response.3,6,7 Many genes are thought to be main-
tained in a poised state in memory T-cells, enabling rapid
re-expression of effector molecules following T-cell reacti-
vation by antigen-presenting cells (APCs). However, epige-
netic alterations to the genome are not fixed and memory
cells can display plasticity.8–11 The level of this plasticity is
likely dependent on the extent of differentiation during the
primary response and on the reactivation environment.
Cytokine responses by memory CD4 T-cells are key to
their ability to protect the host from infectious disease.
Rapid production of the most appropriate cytokine
enables CD4 T-cells to quickly control the pathogen. For
example, interferon (IFN)-c from CD4 T-cells protects
against viral infections, while interleukin (IL)-17 aids con-
trols of bacterial and fungal infections, and IL-4 protects
against infection by parasitic worms.12–20 Most immune
protection studies are carried out in animal models where
challenge studies are feasible and mechanisms of protec-
tion can be identified by loss or gain of function. Human
challenge studies are, however, becoming more frequent
and have also demonstrated that cytokine-producing
memory CD4 T-cells correlate with reduced symptoms
following pathogen challenge.21–23
Immune protection by cytokine-producing CD4 T-cells
correlates with their production of several related cytoki-
nes, with cells producing IFN-c, tumour necrosis factor
(TNF)-a and IL-2 most commonly studied. These
multifunctional memory CD4 T-cells are found following
vaccination or infection in animal models and in
humans.24–29 In infection models of Leishmania major
and Mycobacterium tuberculosis, multifunctional CD4
T-cells provide the most effective immune protection,
and in humans they correlate with successful recovery
from infection with Japanese encephalitis virus.25,27,29
It is currently unclear why multifunctional memory CD4
T-cells offer enhanced protection in comparison to single
cytokine-producing cells. The enhanced protective func-
tions of these cells could be because they produce higher
levels of the individual cytokines on a per cell basis.25,27
Alternatively, or in addition, as multifunctional memory T-
cells can simultaneously drive effector responses, for exam-
ple via IFN-c, and T-cell survival and proliferation via IL-2
production, they offer a sustained and protective response.
Currently we have limited understanding of the priming
signals that lead to the generation of multifunctional mem-
ory cells. This information will be key to the development
of more effective vaccines capable of producing protective
multifunctional CD4 T-cells.
Memory CD4 T-cells are found throughout the
body
The consequences of rapid cytokine production by memory
CD4 T-cells depend on the location of the cell. Na€ıve T-
cells patrol through lymphoid organs as they have no prior
knowledge about where in the body the pathogen they rec-
ognize may cause an infection. Memory T-cells have learnt
this information during the primary response, and some
memory CD4 T-cells, tissue resident memory (Trm) cells,
continue to reside at the infection site. Other memory T-
cells recirculate through the body. These memory cells can
be split into central memory cells (Tcm) and effector mem-
ory cells (Tem). Tcm are largely restricted to lymphoid
organs and the blood. In contrast, Tem are present in the
blood and have the ability to traffic through peripheral
organs. All types of memory CD4 T-cells are important.
This is because they can provide protection in distinct
ways, with recirculating cells acting as reinforcements
should resident cells fail to contain the infection (Fig. 1).
Trm T-cells
The anti-pathogen responses coordinated by na€ıve T-cells
are delayed until information about the infection is trans-
ferred from the infection site to the draining lymph node.
Trm cells can provide much more immediate protection,
and various studies have demonstrated that they provide
the most effective immune protection to the host.14,15,17,30
Tissue resident memory cells are identified as CD69+
cells that remain within peripheral tissues following patho-
gen clearance.30–32 CD69 is thought to act as a retention
signal as it inhibits the surface expression of the sphin-
gosine-1-phosphate (S1P) receptor 1. S1P is a signalling
phospholipid that regulates the migration of immune cells
out of lymph nodes into efferent lymphatics, and also
guides cells out of tissues towards draining lymph
nodes.33–35 Expression of the integrin CD103 by CD8 Trm
cells also contributes to their retention, tethering them to
skin or mucosal epithelial cells; it is, however, more rare
for CD4 Trm cells to express this molecule.36
There are clear differences between CD4 and CD8 Trm
cells first revealed by Gebhardt et al. in mice infected with
herpes simplex virus (HSV).14 While CD8 Trm cells
become dendritic-like with limited motility in the epithe-
lium of the skin, CD4 Trm cells are mainly found in the
dermis and display a more motile behaviour.14 In humans,
Trm cells have been found in multiple organs, with elegant
studies from Farber and colleagues tracking memory T-
cells in individuals of various ages. Human and mouse Trm
cells share many characteristics, including CD69 expression
and reduced expression of S1P receptor 1.37,38 Similarly,
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CD4 Trm cells in skin are, like their mouse equivalent,
mainly found in the dermis.39 Transcriptional analyses
comparing circulating cells and Trm cells from the same
donor indicate that CD69+ and CD69 CD4 T-cells
express overlapping sets of T-cell receptor genes.37 These
data indicate that environment, rather than epitope speci-
ficity, is the key driver of Trm cell development.
In mice, memory T-cell residency is often identified by
their failure to bind fluorescently labelled antibody injected
intravenously shortly before the animal is killed. This
demonstrates that these cells are not directly in contact
with the vasculature, at least at the time of analysis. Three
additional key approaches are used in mice to investigate
whether Trm cells are truly resident: in vivo treatment with
the S1P functional antagonist, FTY720; parabiosis in which
the circulatory systems of two animals are surgically con-
nected; and fate mapping using photoconvertible cells.
Treatment with FTY720 restricts the migration of
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Figure 1. Protective roles of memory CD4 T-cell subsets. The protective response to previously encountered pathogens is dependent on a number
of T-cell subsets. Upon pathogen encounter, resident memory CD4 T-cells (Trm) that can be found in clusters with macrophages or dendritic cells
respond rapidly by proliferating and releasing inflammatory cytokines and chemokines (1). This stimulates the recruitment of circulating effector
memory CD4 T-cells (Tem) to the inflamed tissue to augment the immune response (2). Local antigen-presenting cells (APCs) can subsequently
transport antigen to lymphoid organs where they activate central memory CD4 T-cells (Tcm) (3–4). These central memory T-cells then expand
and recirculate to confer systemic protection or further amplify the response at inflamed tissues. Memory follicular helper T-cells (Tfh) reactivated
by either dendritic cells or B-cells can enter B-cell zones and induce rapid production of class-switched antibodies, which are then released into the
circulation (5). These different memory T-cell subsets work in concert to provide long-lasting protection upon re-exposure to the same pathogen.
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circulating cells, so a stable population of Trm cells in trea-
ted mice demonstrates that these cells are neither replen-
ished by, nor lost to, circulating populations.15,17,40
However, FTY720 may also inhibit egress of cells from
peripheral tissues to draining lymph nodes and/or reduce
cell survival.35,41–43 Despite these potential caveats, results
from FTY720-treated animals reflect those from more ele-
gant parabiosis experiments that demonstrate that Trm
cells are a distinct population neither leaving the tissue nor
being replenished by circulating cells.17,30
In contrast, data from Collins et al. suggest that CD4
Trm cells are a more dynamic population.44 CD4 Trm
cells in mice that express the photoconvertible molecule,
Kaede, were found to migrate from the skin of HSV-
infected mice to draining lymph nodes. These cells lost
expression of CD69 following migration out of the skin.
The migrating cells represented about half of the Trm cell
population photoconverted at the start of the study and
then examined 3 days later. These findings question the
reliability of CD69 as a marker of persistently resident
memory T-cells within tissues. They suggest that at least
two distinct populations may be present – a more static,
true Trm population and a second more dynamic popu-
lation that alter CD69 expression depending on location.
In this study, the specificity of the cells was not deter-
mined. These two populations may, therefore, reflect resi-
dent T-cells that respond to local antigen and remain in
the tissue versus cells that are recruited but are not main-
tained because they are not re-activated by antigen.
Future studies will need to address the functional proper-
ties of these two populations and compare the behaviours
of T-cells exposed to local antigen versus those recruited
by inflammation alone.
To develop vaccines that generate protective CD4 Trm
cells, it is imperative that we understand the signals that
drive the development and maintenance of these cells.
During immune responses, activated T-cells migrate into
inflamed tissues under the guidance of chemokines, inte-
grins and adhesion molecules.45 T-cells that encounter
their antigen at the infection site are likely to receive tis-
sue-specific cues that influence their function and mem-
ory potential. The presentation of specific antigen at the
infected tissue is required for the formation of CD4 Trm
cells, but may not be necessary for CD8 Trm cells.31,46–48
These data indicate that vaccines aimed at generating pro-
tective Trm CD4 T-cells must drive antigen presentation
within the tissue targeted by the pathogen.
Whether persistent antigen presentation following
pathogen control is required to maintain CD4 Trm cells
is still unclear. CD4 Trm cells in the skin and mucosa are
located in clusters of cells with macrophages and/or den-
dritic cells that express chemokines that maintain the cells
at the site. Macrophage-derived CCL5 maintains CD4 T-
cells in the vagina following HSV-2 infection.17 IFN-c
produced by CD4 Trm cells, potentially in response to
low levels of persistent antigen, in turn maintains macro-
phage CCL5 expression. Similarly, CCL5 produced by
CD8 T-cells and macrophages in the skin is responsible
for maintaining CD4 T-cells in perifollicular clusters.44 In
this case, however, antigen presentation was not required
for memory T-cells to be incorporated into these immune
cell clusters.
Clusters of Trm and APCs may represent nascent ver-
sions of ectopic lymphoid structures (ELS), which range
from organized clusters of immune cells to lymph node-
like structures with designated T- and B-cell zones. ELS are
often found in sites of chronic inflammation, and have
been associated with the generation of autoreactive anti-
bodies.49,50 Whether Trm immune cell clusters represent
an early stage in ELS development is unclear. They do pro-
vide an excellent location for the rapid reactivation of CD4
Trm cells by local APCs. For example, influenza virus-spe-
cific Trm cells, which can be found in clusters with B-cells
in the infected lung, provide effective and rapid immune
protection at least in part by providing rapid assistance to
B-cells to make neutralizing antibodies.18
In addition, CD4 Trm cells can enhance the actions of
cells that are recruited into the infected tissue. Influenza-
specific memory CD4 T-cells in the lung drive the pro-
duction of chemokines that attract innate immune cells
that rapidly control viral spread.51 Similarly, IFN-c pro-
duction by L. major-specific CD4 Trm cells drives the
recruitment of inflammatory monocytes to the infection
site.15 These recruited monocytes produce nitric oxide
and reactive oxygen species that are toxic to the parasite.
Recirculating memory T-cells
Circulating antigen-specific CD4 memory T-cells can par-
ticipate in protective immune responses either acting as
reinforcements to Trm cells32 or protecting tissues not
challenged in the initial infection or vaccination.14,52
Immune protection by circulating memory CD4 T-cells is
delayed compared with Trm-mediated protection as they
must be first recruited to the site of infection and reacti-
vated by local APCs. Immune protection by circulating
cells can require collaboration with other components of
the memory immune response. Iijima et al. found that
while recirculating HSV-2-specific memory CD4 T-cells
cannot prevent viral replication at the challenge site, they
could prevent virus entry into the dorsal route ganglia.52
This protection required the entry of virus-specific anti-
body into the nervous system, which was dependent on
increased vascularization mediated by IFN-c derived from
reactivated memory CD4 T-cells. Similarly, in mice vacci-
nated with the yellow fever vaccine, transfer of CD4 T-
cells and immune serum provide the most optimal
immune protection.20
The effector response of recruited antigen-specific
memory CD4 T-cells is likely to be influenced by the level
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of MHC II and co-stimulatory molecules displayed by the
local APC that reactivates the memory cell.53–55 Further-
more, this response is likely to be distinct to that from
the same cell reactivated in the very different environ-
ment of a lymphoid organ. It is key, therefore, to con-
sider not just the type of memory CD4 T-cell that a
vaccine should aim to generate but where it is likely to be
reactivated, which APCs are involved in this, and the
downstream consequences of these interactions.
Memory CD4 T-cells in secondary lymphoid organs
Central memory cells are most likely to be reactivated in
secondary lymphoid organs as they lack the chemokine
receptors and adhesion molecules necessary to enter
peripheral tissues.45 Instead they, like na€ıve T-cells,
express high levels of CD62L, which enables entry into
lymph nodes from the blood via high endothelial venules
and CCR7, the chemokine receptor that is also involved
in trafficking to and within lymphoid organs.45,56
While Tcm cells may not rapidly produce protective
cytokines, they proliferate upon reactivation, quickly
increasing the number of antigen-specific CD4 T-cells.
These cells can then either remain in the lymphoid organ
to help B-cells or migrate to the site of infection to help
tackle the infection directly. As Tcm cells are uncommit-
ted to any particular effector cytokine production, they
can differentiate under the influence of the cytokine
milieu triggered by the challenge infection.57 Vaccines
that drive the generation of Tcm cells may provide less
immediate protection than those designed to induce Trm
cells; however, they offer an adaptable pool of memory
CD4 T-cells that can protect via multiple pathways.
In primary immune responses, activated CD4 T-cells
drive B-cell germinal centre reactions leading to the pro-
duction of high-affinity class-switched antibody. The cells
that coordinate this response are classed as T follicular
helper (Tfh) cells that are initially formed in the T-cell
zone of the lymphoid organ before moving to the devel-
oping germinal centre.7 Depending on the type of infec-
tion, Tfh cells can produce T helper type 1 or 2 cytokines
to drive appropriate antibody class switching.7
Whether Tfh cells can differentiate into specialized mem-
ory cells has been an area of recent debate.7 Within the pool
of Tcm cells, a proportion of cells express higher levels of
CXCR5, the chemokine receptor that allows cells to move
towards or into B-cell follicles.7 Tfh cells can remain for
many months in the original draining lymph node where
persistent antigen is likely to maintain them in an active
state. These cells rapidly expand upon re-challenge and may
represent a population of lymph node resident memory cells
as they can express CD69.58–60 However, this reliance on
antigen suggests that these lymph node resident Tfh cells
may not represent ‘true resting memory cells’. Moreover,
Pepper et al. found that the number of antigen-specific
memory cells that expressed Tfh markers declined over time,
suggesting that Tfh cells fail to differentiate into long-lived
memory cells.57 However, we and others have shown that
both mouse and human CXCR5+ memory CD4 T-cells pro-
vide rapid assistance to B-cells upon reactivation.61–69
Importantly, Alexander et al. demonstrated that DNA vacci-
nation generated memory CD4 T-cells that, via their rapid
assistance to B-cells, protected mice from influenza virus
infection.70 This rapid assistance to generate high-affinity
class-switched antibody is particularly relevant to infections
such as influenza virus where regions of the virus targeted by
antibody alter much more rapidly than epitopes recognized
by CD4 T-cells.71
CXCR5+ memory cells with an increased ability to help
B-cells are commonly referred to as Tfh memory cells,7
even though they may be found in circulation rather than
contained within a B-cell follicle. How they are distinct
from the general CD4 Tcm pool is a complicated question.
Indeed, Tfh memory cells do express lower levels of CXCR5
than Tfh cells present during the primary immune
response62,69 and, as Pepper et al. describe, are difficult to
distinguish from Tcm cells.57 Reactivation of CXCR5+
memory cells can occur in the absence of B-cells,63 but
reactivation by B-cells consolidates the T-cell’s expression
of Bcl6, the transcription factor associated with Tfh cell
function.72 These data suggest that if there are Tfh memory
cells, their function upon reactivation is likely dependent
on the context in which they are reactivated.
A further key question that remains to be addressed is the
consequences of reactivation of memory CD4 T-cells by B-
cells within either ELS or immune cell clusters at the infec-
tion site itself. In lymphoid organs, secondary germinal cen-
tres are thought to be formed by reactivated IgM+ memory
B-cells, providing a blank canvas for antibody class switching
relevant to the pathogen.73 In influenza virus-infected mice,
CD4 T-cells and B-cells can be found in clusters within the
lung, and many virus-specific B-cells in the lung are class
switched.74,75 This suggests that germinal centres formed in
ELS in peripheral tissues may follow different rules to those
in lymphoid organs following re-infection. Careful studies
that dissect the contribution of the reactivation of B-cells in
the tissue versus those in lymph nodes to immune protec-
tion are needed to establish their relative importance in pro-
tecting the host from reinfection.
Human vaccines: recent progress and continuing
challenges
Dissecting the relative contributions of different popula-
tions of memory T-cells to immune protection in mice
provides mechanistic understanding of immunological
memory. Animal vaccine studies often do not, however,
easily translate into protective vaccines for humans.
Human challenge studies, therefore, play important roles
in evaluating vaccines at early stages of development.
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They often cut the costs of large-scale field vaccine trials
and reduce tests of non-effective vaccines on large num-
bers of individuals.76 This is especially the case in dis-
eases, including malaria and tuberculosis, in which our
understanding of the correlates and mechanisms of
immune protection are limited.
Human challenge studies in malaria have demonstrated
the relative safety and efficacy of sporozoite vaccines.
Experimental sporozoite vaccines have either been deliv-
ered as irradiated parasites that can infect host cells but fail
to differentiate and cause disease, or as live parasites.21,77,78
In this instance, anti-malarial drugs must be given to pre-
vent active disease. Protection in these studies is associated
with high levels of multifunctional, antigen-specific mem-
ory CD4 T-cells in peripheral blood, although mouse and
non-human primate studies point to key roles for liver resi-
dent memory CD8 T-cells in preventing parasite
growth.78,79 The logistical challenges of sporozoite vaccines
are significant; current field trials are likely to reveal
whether or not these approaches are feasible.80
The most advanced vaccine for malaria is
GlaxoSmithKline’s RTS,S vaccine, which contains the cir-
cumsporozoite protein from the pre-erythrocyte stage of
the parasite.81,82 Antibodies and CD4 T-cells specific to
the circumsporozoite protein are correlates of immune
protection following RTS,S immunization, which has an
efficacy of about 30%.22,81,83 While a positive advance,
this relatively low efficacy and the short duration of pro-
tection means that more robust vaccines are still
required.84 A key contrast between sporozoite vaccines
and the recombinant protein RTS,S vaccine is the need
for adjuvants to boost the immune response to the sub-
unit vaccine. RTS,S contains a combined adjuvant with a
saponin and toll-like receptor agonist.82 This adjuvant
combination is one of only a handful approved for use in
humans, with few able to induce the size and correctly
tailored immune response driven by either natural infec-
tion or vaccination with an attenuated or inactivated
pathogen.82 The live vaccines are, however, more likely to
lead to adverse effects or negative side-effects.82,85
Improved understanding of the mechanisms of action of
current and experimental adjuvants is likely to lead to
further improvements allowing us to strike the right bal-
ance between immunogenicity and vaccine safety.
Other human challenge models include the use of BCG
as a surrogate challenge in tuberculosis vaccine trials.
While the BCG vaccine protects against disseminated
tuberculosis, especially in young children who are most at
risk, its ability to protect from pulmonary disease varies
across the world.86 Current studies in mice, non-human
primates and humans are focussed on increasing the
immune protection offered by BCG, for example by using
prime-boost strategies.86,87 BCG effectiveness can also be
achieved by altering the vaccination route, with mucosal
and intravenous routes offering enhanced protection
compared with more traditional subcutaneous or intra-
dermal injection in a non-human primate model.88
Potentially these injection routes provide enhanced pro-
tection as they are better at driving the development of
CD4 Trm cells in the lung.
Human immunodeficiency virus presents bigger hurdles
still as immune protection does not develop in the vast
majority of infected individuals and human challenge
studies are not possible. The RV144 HIV vaccine trial has
offered a number of key insights into immunity to HIV.
The vaccine demonstrated an efficacy of 312%.89 Protec-
tion correlated with high levels of anti-viral IgG, depen-
dent on CD4 T-cell responses, while vaccine-driven IgA
was associated with an increased risk of infection.90–92
Immune protection to this highly diverse virus is thought
to require broadly neutralizing antibodies (bnAbs) that
recognize more conserved regions of the virus.93 The
development of bnAbs likely requires repeated exposure
to the antigen and continued input from Tfh cells.93 Suc-
cessful HIV vaccines will probably, therefore, require the
induction of effective Tfh memory cells that can coordi-
nate the development of protective bnAbs.
Future perspectives
We have appreciated the concept of protective immuno-
logical memory for thousands of years and have been
manipulating it via vaccination since the 10th century.85
The majority of successful vaccines act by generating neu-
tralizing class-switched antibodies produced by long-lived
plasma cells.1 These vaccines must, therefore, drive activa-
tion of helper CD4 T-cells that act, at the very least, dur-
ing the primary response to protect the host. We are now
beginning to understand the potential myriad roles mem-
ory CD4 T-cells can themselves play in protection from
infectious diseases. The recent studies discussed here have
revealed the complexity of the memory CD4 T-cell pool.
We now need to understand how vaccine formation and
delivery can be altered to bias the development of protec-
tive memory CD4 T-cells.
As our fundamental understanding of memory CD4 T-
cells improves, we must put this into a real-world context.
Studies in wild or pet-shop mice have highlighted the
major differences between memory compartments and
responses to infections in these animals versus their labo-
ratory equivalent.94,95 The microbiome plays a major role
in these differences, but the exposure to varied and multi-
ple pathogens throughout life is also likely to affect the
generation and function of immune memory cells.94,95
Human challenge studies offer a valuable extra arm to
vaccine studies, but most are carried out on healthy west-
ern volunteers. Evidence from the recently introduced
rotavirus vaccine, and also polio and cholera vaccine stud-
ies, demonstrates reduced vaccine-effectiveness in major
at-risk populations in low–middle-income countries.96–98
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It is clear, therefore, that protective immunity must be
examined and evaluated in multiple experimental settings
that can each provide valuable information on both mech-
anisms of immune protection and real-world effectiveness.
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